Elucidating genomic characteristics of lung cancer progression from in situ to invasive adenocarcinoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Vinayanuwattikun, Chanida ^a,b   Le Calvez Kelm, Florence ^a   Abedi Ardekani, Behnoush ^a   Zaridze, David ^c   Mukeria, Anush ^c   Voegele, Catherine ^a   Vallée, Maxime ^a,d   Purnomosari, Dewajani ^a,e   Forey, Nathalie ^a   Durand, Geoffroy ^a   Byrnes, Graham ^a   McKay, James ^a   Brennan, Paul ^a   Scelo, Ghislaine ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^d University Laval   (Canada)

^e GADJAH MADA UNIVERSITY   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADENOCARCINOMA; AGED; FEMALE; GENETICS; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; TUMOR INVASION;

ADENOCARCINOMA; AGED; APOBEC DEAMINASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84983372433     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31628     Document Type: Article

References (58)

1. Witt, C. European respiratory society/american thoracic society/international association for the study of lung cancer international multidisciplinary classification of lung adenocarcinoma: state of the art. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 6, 1451, doi: 10.1097/JTO.0b013e318224643b (2011).
2. Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306-313, doi: 10.1038/nature10762 (2012).
3. Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature genetics 38, 468-473, doi: 10.1038/ng1768 (2006).
4. Izumchenko, E. et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nature communications 6, 8258, doi: 10.1038/ncomms9258 (2015).
5. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature biotechnology 31, 213-219, doi: 10.1038/nbt.2514 (2013).
6. Genomes Project, C. et al. An integrated map of genetic variation from 1, 092 human genomes. Nature 491, 56-65, doi: 10.1038/nature11632 (2012).
7. Exome Variant Server NHLBI GO Exome Sequencing Project (ESP) Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) [22/12/14 accessed].
8. Suspene, R. et al. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proceedings of the National Academy of Sciences of the United States of America 108, 4858-4863, doi: 10.1073/pnas.1009687108 (2011).
9. Shinohara, M. et al. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Scientific reports 2, 806, doi: 10.1038/srep00806 (2012).
10. Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nature genetics 45, 970-976, doi: 10.1038/ng.2702 (2013).
11. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120, doi: 10.1016/j.cell.2012.08.029 (2012).
12. Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550, doi: 10.1038/nature13385 (2014).
13. Weir, B. A. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898, doi: 10.1038/nature06358 (2007).
14. Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome biology 12, R41, doi: 10.1186/gb-2011-12-4-r41 (2011).
15. Kang, J. U., Koo, S. H., Kwon, K. C., Park, J. W. & Kim, J. M. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer genetics and cytogenetics 182, 1-11, doi: 10.1016/j.cancergencyto.2007.12.004 (2008).
16. McKay, J. D. et al. Lung cancer susceptibility locus at 5p15.33. Nature genetics 40, 1404-1406, doi: 10.1038/ng.254 (2008).
17. Wang, Z. et al. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human molecular genetics 23, 6616-6633, doi: 10.1093/hmg/ddu363 (2014).
18. Haiman, C. A. et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nature genetics 43, 1210-1214, doi: 10.1038/ng.985 (2011).
19. Kote-Jarai, Z. et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature genetics 43, 785-791, doi: 10.1038/ng.882 (2011).
20. Petersen, G. M. et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature genetics 42, 224-228, doi: 10.1038/ng.522 (2010).
21. Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nature genetics 45, 1134-1140, doi: 10.1038/ng.2760 (2013).
22. Qi, Q. & Ye, K. The roles of PIKE in tumorigenesis. Acta pharmacologica Sinica 34, 991-997, doi: 10.1038/aps.2013.71 (2013).
23. Motadi, L. R., Bhoola, K. D. & Dlamini, Z. Expression and function of retinoblastoma binding protein 6 (RBBP6) in human lung cancer. Immunobiology 216, 1065-1073, doi: 10.1016/j.imbio.2011.05.004 (2011).
24. Mishra, R. R., Chaudhary, J. K. & Rath, P. C. Cell cycle arrest and apoptosis by expression of a novel TPIP (TPIP-C2) cDNA encoding a C2-domain in HEK-293 cells. Molecular biology reports 39, 7389-7402, doi: 10.1007/s11033-012-1571-6 (2012).
25. Mishra, R. R., Chaudhary, J. K., Bajaj, G. D. & Rath, P. C. A novel human TPIP splice-variant (TPIP-C2) mRNA, expressed in human and mouse tissues, strongly inhibits cell growth in HeLa cells. PloS one 6, e28433, doi: 10.1371/journal.pone.0028433 (2011).
26. Bamford, S. et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. British journal of cancer 91, 355-358, doi: 10.1038/sj.bjc.6601894 (2004).
27. Futreal, P. A. et al. A census of human cancer genes. Nature reviews. Cancer 4, 177-183, doi: 10.1038/nrc1299 (2004).
28. Sholl, L. M. et al. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in neversmokers. Cancer research 69, 8341-8348, doi: 10.1158/0008-5472.CAN-09-2477 (2009).
29. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075, doi: 10.1038/nature07423 (2008).
30. Zhang, X. & Chang, A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. International journal of medical sciences 5, 209-217 (2008).
31. Berger, A. H. et al. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene 33, 4418-4423, doi: 10.1038/onc.2013.581 (2014).
32. Li, J. T. et al. [Mutation and amplification of RIT1 gene in hepatocellular carcinoma]. Zhonghua yi xue yi chuan xue za zhi =Zhonghua yixue yichuanxue zazhi =Chinese journal of medical genetics 21, 43-46 (2004).
33. Brooks, A. N. et al. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PloS one 9, e87361, doi: 10.1371/journal.pone.0087361 (2014).
34. Hernandez, J. et al. Tumor suppressor properties of the splicing regulatory factor RBM10. RNA biology, 0, doi: 10.1080/15476286.2016.1144004 (2016).
35. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling 6, pl1, doi: 10.1126/scisignal.2004088 (2013).
36. National Research Institute (NCI) and National Human Genome Research Institute (NHGRI), The Cancer Genome Atlas (TCGA) URL; http://tcga-data.nci.nih.gov/tcga/[03/03/2015 accessed].
37. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94, doi: 10.1038/nature09807 (2011).
38. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256, doi: 10.1126/science.1253462 (2014).
39. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259, doi: 10.1126/science.1256930 (2014).
40. Kim, H. et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome research 25, 316-327, doi: 10.1101/gr.180612.114 (2015).
41. Eleveld, T. F. et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature genetics 47, 864-871, doi: 10.1038/ng.3333 (2015).
42. Andor, N. et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nature medicine 22, 105-113, doi: 10.1038/nm.3984 (2016).
43. Leica Biosystems, Aperio ImageScope URL; www.leicabiosystems.com/digital-pathology/digital-pathology-management/imagescope/[03/03/2015 accessed].
44. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic acids research 38, e164, doi: 10.1093/nar/gkq603 (2010).
45. Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Human mutation 36, E2423-2429, doi: 10.1002/humu.22771 (2015).
46. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501, doi: 10.1038/nature12912 (2014).
47. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic acids research 39, D945-950, doi: 10.1093/nar/gkq929 (2011).
48. Liu, X., Jian, X. & Boerwinkle, E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Human mutation 34, E2393-2402, doi: 10.1002/humu.22376 (2013).
49. Broad Institute, MA, ReCapSeg (URL: http://gatkforums.broadinstitute.org/gatk/discussion/5640/recapseg-overview#latest) [23/01/2016 accessed].
50. Venkatraman, E. S. & Olshen, A. B. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23, 657-663, doi: 10.1093/bioinformatics/btl646 (2007).
51. Yu, G. & He, Q. Y. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Molecular bioSystems 12, 477-479, doi: 10.1039/c5mb00663e (2016).
52. Fabregat, A. et al. The Reactome pathway Knowledgebase. Nucleic acids research 44, D481-487, doi: 10.1093/nar/gkv1351 (2016).
53. Gaujoux, R. & Seoighe, C. A flexible R package for nonnegative matrix factorization. BMC bioinformatics 11, 367, doi: 10.1186/1471- 2105-11-367 (2010).
54. Wellcome Trust Sanger Institute, COSMIC Catalogue of somatic mutations in cancer http://cancer.sanger.ac.uk/cosmic/signatures [31/03/2015 accessed].
55. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell reports 3, 246-259, doi: 10.1016/j.celrep.2012.12.008 (2013).
56. Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 26, 64-70, doi: 10.1093/annonc/mdu479 (2015).
57. Li, H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 27, 2987-2993, doi: 10.1093/bioinformatics/btr509 (2011).
58. Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nature methods 11, 396-398, doi: 10.1038/nmeth.2883 (2014).